[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100603643":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":10,"centralContacts":34,"locations":10,"responsibleParty":44,"collaborators":10,"id":48,"slug":49,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":50,"sex":55,"minAge":10,"maxAge":10,"enrollmentInfo":56,"targetDuration":10,"studyType":59,"phases":10,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":65,"whyStopped":10,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":10},{"fullName":5,"class":6},"Assiut University","OTHER",[8,16],{"label":9,"type":10,"description":11,"interventionNames":12},"The case group: (30 cases)",null,"is comprised of patients with diabetes mellitus suffering from Charcot foot and diagnosed clinically.",[13,14,15],"Diagnostic Test: Diagnosis of Charcot foot disease","Diagnostic Test: Hematologic and biochemical parameters,","Diagnostic Test: ELIZA Assay",{"label":17,"type":10,"description":18,"interventionNames":19},"The control group: (30 cases)","is comprised DM patients without Charcot foot.",[14,15],[21,26,30],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":10},"DIAGNOSTIC_TEST","Diagnosis of Charcot foot disease","Diagnosis of Charcot foot disease will be obtained from the results of physical examination and according to x-ray examination of foot which was performed at the Radiology Department of Assiut University Hospital. The Eichenholtz classification system, developed by Sidney N. Eichenholtz in 1966, categorizes Charcot arthropathy (also known as Charcot foot) into three stages based on clinical and radiographic findings. These stages are development, coalescence, and reconstruction",[9],{"type":22,"name":27,"description":28,"armGroupLabels":29,"otherNames":10},"Hematologic and biochemical parameters,","Hematologic and biochemical parameters, including lymphocyte, monocyte, neutrophil, and platelet counts, as well as glucose, HbA1c, triglyceride (TG), HDL, and LDL levels, will be extracted from patient records.\n\nNLR=absolute neutrophil count (109\u002FL)\u002Fabsolute lymphocyte count (109\u002FL), PLR=platelet count (109\u002FL)\u002Fabsolute lymphocyte count (109\u002FL), LMR=absolute lymphocyte count (109\u002FL)\u002Fabsolute monocyte count (109\u002FL), GLR=glucose (mg\u002FdL)\u002Fabsolute lymphocyte ratio (109\u002FL), TGR=triglyceride (mg\u002FdL)\u002Fglucose ratio (mg\u002FdL), THR=triglyceride (mg\u002FdL)\u002FHDL ratio (mg\u002FdL), SIRI = absolute neutrophil count (109\u002FL) × absolute monocyte count (109\u002FL)\u002F absolute lymphocyte count (109\u002FL), SII = platelet count (109\u002FL) × absolute monocyte count (109\u002FL)\u002Fabsolute lymphocyte count (109\u002FL), TyG index = fasting triglyceride (mg\u002FdL) × fasting plasma glucose (mg\u002FdL)\u002F2, PIV =absolute neutrophil count (109\u002FL) × platelet count (109\u002FL) × absolute monocyte count (109\u002FL)\u002Fabsolute lymphocyte count (109\u002FL).",[9,17],{"type":22,"name":31,"description":32,"armGroupLabels":33,"otherNames":10},"ELIZA Assay","For each patient, 2 ml of blood will be obtained. The serum levels of IL-10, TNF-α will be assessed by using (ELISA) kit obtained from (Biodiagnostic company, Egypt) according to the manufacturer protocol.",[9,17],[35,40],{"name":36,"role":37,"phone":38,"phoneExt":10,"email":39},"Dr. Refaat Fathy Abdel-Aal Naseer, Prof","CONTACT","+201011121526","refaat.fathy@med.aun.edu.eg",{"name":41,"role":37,"phone":42,"phoneExt":10,"email":43},"Mohammed Hasan Mohammed AbdEllah-Alawi, Dr.","+201115353591","mhmdifferent@aun.edu.eg",{"type":45,"investigatorFullName":46,"investigatorTitle":47,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Amr Mohamed Ali Mohamed","Principal Investigator","100603643","risk-factor-analysis-for-charcot-foot-in-patients-with-diabetes-mellitus-the-interplay-of-inflammatory-cytokines-and-metabolic-factors-100603643",false,"NCT07139184","Risk Factor Analysis for Charcot Foot in Patients With Diabetes Mellitus: The Interplay of Inflammatory Cytokines and Metabolic Factors","RFA-CF-DM-ICMF","Inclusion . Inclusion criteria:\n\n* Adult Patients who are diagnosed with DM who are willing to participate in the study with informed consent form.\n\n  b. Exclusion criteria:\n* Patients with neuritis \u002F neuropathy of the lower extremity due to other causes other than DM\n* Significant trauma that may cause peripheral nerve damage.\n* Patient with routine use of corticosteroid\n* Previous history of smoking\n* Patients with chronic renal impairment due to diseases other than DM (creatinine \\> 1.4 mg\u002FdL), previous myocardial infarction or stroke, history of cancer.\n* Patients with iron deficiency anemia or uremia affecting HbA1c levels or elevated triglyceride or bilirubin levels.\n* Patients diagnosed with neurological disease, malignancy.","ALL",{"count":57,"type":58},60,"ESTIMATED","OBSERVATIONAL","Diabetes mellitus (DM) is among the most common metabolic disorders globally. According to the data from international research, the number of persons with diabetes mellitus reached 366 million in 2011 and is predicted to increase to 552 million by 2030.",[62],"Charcot Foot",[64],"Charcot Foot Diabetes Mellitus TNF alpha IL 10","NOT_YET_RECRUITING","2025-08-17",{"date":68,"type":69},"2025-08-24","ACTUAL",{"date":71,"type":58},"2025-10",{"date":73,"type":58},"2027-10",{"name":5,"class":6}]